Entera Bio ENTX
NASDAQ ENTX
$2.91 +0.22 (+8.18%)
At close: Sep 30, 2026 · 4:00 PM EDT

Entera Bio (ENTX) Current Deferred Revenue (2020 - 2021)

Updated

Entera Bio (ENTX) reported Current Deferred Revenue of $15,000 for Q4 2021, down 90.5% from $158,000 a year earlier.

Analysis

Entera Bio (ENTX) Current Deferred Revenue (2020 - 2021) Analysis & Trends

  • By year, Current Deferred Revenue came in at $158,000 in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Entera Bio 132.59 Mn 101.46 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 15,000.00
Dec 31, 2020 158,000.00
API Access

Entera Bio Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ENTX&period=max&api_key=YOUR_API_KEY